In the first quarter of 2024, pharmaceutical company Teva posted revenues of $3.81 billion, representing a growth of 4.3% compared to the same period last year. This revenue exceeded analysts’ forecasts by $18 million. Despite this, Teva recorded a net loss attributable to shareholders of $139 million according to GAAP, an improvement from the loss of $220 million in the corresponding quarter. Non-GAAP net profit was $548 million, up 20% compared to the previous quarter.
Teva’s CEO, Richard Francis, announced that revenue growth in local currency terms was driven by increases in generic drugs and originator drugs Ostedo and Ajobi. The company also reported separate results for the US market, showing revenue growth of approximately $1.7 billion and profitability of $350 million. In Europe, sales grew by 7.4% to $1.27 billion with profitability increasing by 22.6% to $423 million. International markets also saw sales growth of 2.8% to $597 million with a profit of $117 million
In the Ruhr area of Germany, a tragic accident occurred on Saturday, resulting in the…
In the midst of ongoing disagreements within the Israeli unity government, two offensives by Israeli…
Davis Medical Center, established in 1903 with a generous gift from the Henry Gassaway Davis…
Electricity prices in Finland are currently at historically low levels due to a combination of…
As the conflict in Ukraine persists, the Russian military has intensified its efforts to achieve…
In recent news, the Canadian Security Intelligence Service (CSIS) has issued a warning to citizens…